Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZOSTAVAX in healthy adults in India
NCT01527370Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2012
- Primary completion
- Apr 2013
- Modality
- Live Attenuated Vaccines
01
Overview
Phase 3, open-label, single-arm trial of varicella virus vaccine live in herpes zoster (HZ), sponsored by Merck & Co. Primary endpoints: Geometric Mean Titer of Varicella-zoster Virus Antibody at 6 weeks, Geometric Mean Fold Rise in VZV Antibody Titers at 6 weeks and 1 more. Started Oct 2012; status: completed.
02
Drugs
varicella virus vaccine live
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT01527370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01527370.